Literature DB >> 22705396

The potential of nicotinic enhancement of cognitive remediation training in schizophrenia.

Britta Hahn1, James M Gold, Robert W Buchanan.   

Abstract

Cognitive deficits in schizophrenia are critically important predictors of long-term psychosocial outcome and are not significantly ameliorated by currently available medications. Cognitive remediation training has shown promise for alleviating cognitive symptoms of schizophrenia, but the clinical significance has often been limited by small effect sizes. Approaches that achieve larger improvement involve time requirements that can be cost-prohibitive within the current clinical care system. This mini-review evaluates the theoretical potential of a pharmacological enhancement strategy of cognitive remediation training with nicotinic acetylcholine receptor (nAChR) agonists. nAChR agonists can facilitate sensory processing, alertness, attention, learning and memory. While these effects may be too subtle and short-lasting to be of clinical relevance as a primary treatment of cognitive deficits, they constitute an ideal effects profile for enhancing training benefits. Several mechanisms are described through which repeated coupling of cognitive training challenges with nAChR stimulation may enhance and accelerate cognitive remediation training effects, advancing such interventions into more effective and practicable treatments of some of the most debilitating symptoms of schizophrenia. This article is part of a Special Issue entitled 'Cognitive Enhancers'.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22705396     DOI: 10.1016/j.neuropharm.2012.05.050

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  6 in total

1.  Neurobiological impact of nicotinic acetylcholine receptor agonists: an activation likelihood estimation meta-analysis of pharmacologic neuroimaging studies.

Authors:  Matthew T Sutherland; Kimberly L Ray; Michael C Riedel; Julio A Yanes; Elliot A Stein; Angela R Laird
Journal:  Biol Psychiatry       Date:  2015-01-07       Impact factor: 13.382

Review 2.  Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia.

Authors:  Jared W Young; Mark A Geyer
Journal:  Biochem Pharmacol       Date:  2013-07-12       Impact factor: 5.858

3.  Nicotine effects on cognitive remediation training outcome in people with schizophrenia: A pilot study.

Authors:  Britta Hahn; Megan E Shrieves; Marie B Yuille; Robert W Buchanan; Ashleigh K Wells
Journal:  Psychiatry Res       Date:  2019-07-29       Impact factor: 3.222

4.  A test of the cognitive self-medication hypothesis of tobacco smoking in schizophrenia.

Authors:  Britta Hahn; Alexander N Harvey; Marta Concheiro-Guisan; Marilyn A Huestis; Henry H Holcomb; James M Gold
Journal:  Biol Psychiatry       Date:  2013-05-06       Impact factor: 13.382

5.  Reward learning as a potential target for pharmacological augmentation of cognitive remediation for schizophrenia: a roadmap for preclinical development.

Authors:  Dean T Acheson; Elizabeth W Twamley; Jared W Young
Journal:  Front Neurosci       Date:  2013-06-18       Impact factor: 4.677

Review 6.  Sensory disturbances, inhibitory deficits, and the P50 wave in schizophrenia.

Authors:  Premysl Vlcek; Petr Bob; Jiri Raboch
Journal:  Neuropsychiatr Dis Treat       Date:  2014-07-14       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.